Bryce Point Capital LLC Purchases Shares of 96,550 Roivant Sciences Ltd. (NASDAQ:ROIV)

Bryce Point Capital LLC acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 96,550 shares of the company’s stock, valued at approximately $1,142,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC increased its stake in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after buying an additional 1,507 shares during the period. Quarry LP increased its stake in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after buying an additional 2,500 shares during the period. Blue Trust Inc. raised its holdings in Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after buying an additional 6,667 shares during the last quarter. Finally, HighTower Advisors LLC purchased a new stake in Roivant Sciences during the 4th quarter valued at $121,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 2.3 %

Shares of ROIV opened at $10.08 on Thursday. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06. The firm’s 50-day moving average price is $10.67 and its 200-day moving average price is $11.36. The firm has a market capitalization of $7.19 billion, a price-to-earnings ratio of -67.20 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, research analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were acquired at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. The trade was a 21.11 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the completion of the sale, the chief operating officer now owns 732,294 shares in the company, valued at approximately $8,260,276.32. This trade represents a 12.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,395,541 shares of company stock worth $15,028,538 over the last ninety days. 7.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $17.10.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.